Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
"Avita share price dives 16% on net loss"
"medical technology company’s shares are falling following today’s financial results"
https://www.fool.com.au/2022/08/12/avita-share-price-dives-16-on-net-loss/
They may go broke with more "great" news_like_this: "GAAP EPS of negative $0.25 " The Street demands audited earnings these days. Div payers are far out performing. And negative earnings are Losses.
I just checked the pre-market price in my TDA account. less than 7k trades and the price dropped to 6.90. Go figure.
AVITA Medical GAAP EPS of -$0.25 beats by $0.15, revenue of $8.34M beats by $1.18M
AVITA Medical (AVHHL) plans to submit PMA supplement for this new indication to FDA by the end of 2022
VALENCIA, Calif. and MELBOURNE, Australia, Aug. 11, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (Company), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, today announced topline results from its pivotal randomized, controlled trial evaluating the safety and effectiveness of the RECELL System combined with meshed autograft for reduction of donor skin harvesting in soft tissue reconstruction. Injuries considered for the clinical trial included any full-thickness acute skin defect, such as degloving or peeled back skin injuries, road rash, surgical wounds, and flesh-eating disease.
“Soft-tissue injuries can be challenging to treat and I am very pleased with the outcomes using RECELL – especially the use of less donor skin when treating a variety of injuries,” said Dr. Steven E. Mapula, Assistant Professor of Surgery TCU and Division Chief of Plastic Surgery at John Peter Smith Hospital. “Following FDA approval, I look forward to utilizing RECELL broadly to help patients with a wide variety of soft-tissue injuries.”
The study design included co-primary endpoints, based on pairwise comparisons where each subject received both RECELL used in combination with widely-meshed skin grafting and the Control treatment of conventional skin grafting; one endpoint had a hypothesis of superiority for donor skin sparing and the other co-primary endpoint had a hypothesis of non-inferiority for healing. Preliminary review of adverse events shows consistency with our years of prior RECELL experience, reinforcing the product’s compelling safety profile. The primary study outcomes are as follows:
The donor sparing endpoint was met, showing a superior ratio of treated injury area to donor site area (p<0.001) with RECELL versus Control
The healing endpoint did not reach pre-specified statistical non-inferiority, however, observed values for healing with RECELL were the same or slightly better than Control
“Our study has shown statistically superior donor sparing and comparable healing rates for RECELL treatment of soft tissue injuries and we are confident in moving forward with our plan for a PMA submission later this year,” said Dr. Mike Perry, Chief Executive Officer of AVITA Medical. “The RECELL System has been used to effectively treat serious burn injuries and we anticipate that the RECELL System will be well-positioned to treat patients with soft-tissue injuries, pending FDA review and approval.”
The Company also plans to submit detailed results from the trial for peer-reviewed publication.
Skin grafting is the standard of care for soft tissue reconstruction, including post-trauma and post-surgical skin reconstruction. Skin grafting requires the harvesting of donor skin, resulting in an additional wound to the patient. Significant pain, delayed healing, risk of infection, the need for multiple procedures, discoloration and scarring are associated with donor site wounds. The total addressable market (“TAM”) for soft tissue repair is approximately $1 billion and more than twice as large as the TAM for burns. Further, if FDA approved, the existing reimbursement codes utilized for burn treatment with the RECELL System will apply to this indication.
AVITA Medical, Inc. Second Quarter 2022 Earnings Conference Call
8/11/2022, 4:00:00 PM CDT
https://register.vevent.com/register/BIf7194e08023144519bdc1637b8691927
Dr. Fiona Wood is working on a scar-less wound healing cream.
https://www.uwa.edu.au/news/Article/2022/May/Volunteers-needed-to-trial-scar-less-wound-healing-cream
I wonder why this is not part of Avita Medical.
Pretty compelling stuff. Thanks for posting.
RCEL: Son of a ----. I'm in!
This stock is a miracle. I love it.
$RCEL
#RCEL
https://www.fool.com.au/2022/08/03/why-is-the-avita-medical-share-price-tracking-20-higher-today/
These guys don't know. There was an article from a random internet guy saying it was his favorite bio stock for August. It has had a pretty good move down for what I consider to be a pretty promising product. Earnings and the call will hopefully clear things up a bit.
https://www.msn.com/en-us/health/medical/avita-medical-may-be-the-hidden-gem-of-biotech-stocks/ar-AA10bv7u
Maybe others are seeing what you see. All time high was 7x higher than close yesterday.
Just noticed that the Aussie stop jumped up over 21% so far tonight. Any new news out to justify that?
It is an article about Avita. Not my top stock but I do like it.
You feel free to flame away with your usual grace though.
"This Small-Cap Biotech Is My Top Stock to Buy in August"
https://www.msn.com/en-us/health/medical/this-small-cap-biotech-is-my-top-stock-to-buy-in-august/ar-AA10bv7u
RCEL: I am considering buying droves of Avita Medical
I like Avita Medical ($RCEL) in every capacity, and based on all rational and/or ethical investment measures.
A spray-on skin solution for burn victims, skin cancer, etc. The spray reverses burns to normal skin? It's revolutionary. Could this become the next trillion dollar company?
It is also being shown to be in research demand by the elderly in surgical methods to achieve young skin again. This makes $RCEL pretty historic.
$RCEL (non-speculatively buying)
#RCEL (non-speculatively buying)
You don’t need to be an MD to run a world-class biotech or pharma if that’s what you’re implying.
Veterinarians are scientists. Some of the most amazing American companies are led by scientists. Not lawyers. Not accountants. Not engineers.
Among the top of that list is Pfizer, whose longtime CEO Albert Bourla, is a veterinarian himself.
I just read this summary from the investor briefing:
AVITA Medical Investor Webinar @ 9pm.
https://us06web.zoom.us/webinar/register/tZUtf-mprDgqEtAvZ4smb0zEHckSxUbZAxdM/success?user_id=QM2HECKaSve5PicVqFK0hQ&timezone_id=Australia%2FSydney
Firms with plenty of cash (RCEL), with no debt and no desire to go into debt (RCEL), with a cash runway until likely profitability based on projected cash burn (RCEL), with no desire to raise cash at the current SP (RCEL) should fare well in this environment.
Avita’s CEO is paid a fraction of median biotech CEO pay.
Avita is setting up multiple revenue streams to achieve higher LONG TERM shareholder value. Future indications (post 2023) will require minimum investment since Avita will form partnerships to help cover the costs of trials etc. So after sales start with Vitiligo and Soft Tissue Regeneration, it’s off to the races without the big trial expenses. I think you see how a successful launch could lead to profitability sooner rather than later, maybe by late 2024 perhaps? 4 revenue streams trumps today’s 1 revenue stream, so I look forward to the results of management’s hard work. Current US Burns revenue alone (with high trial costs) vs US/Japan Burns (late 2022), US stable Vitiligo repigmentation (late 2023), and US soft tissue reconstruction (late 2023) revenue streams. More low-cost indications to come in the future. This is indeed an oversold star in the making.
If anyone has questions about CEO pay this link is the result of a study.
https://www.epi.org/publication/reining-in-ceo-compensation-and-curbing-the-rise-of-inequality/
“The research firm also found typical CEO compensation has nearly doubled since 2019. Median compensation rose from $2.8 million in 2019 to $5.1 million in 2021; the average pay level jumped from $4.7 million to $8.1 million in that timespan. MyLogIQ's CEO, Ganesh Rajappan, told Insider this jump in biopharma CEO pay outpaced the S&P 500.”
And you thought Avita’s CEO was overpaid because some bashers on a forum told you so.
https://www.businessinsider.com/list-top-paid-pharma-and-biotech-ceos-2022-5#bridgebio-pharma-ceo-neil-kumar-25626959-1
Avita’s CEO gets what? $1.2 million?
So with the approval of Recell and the JAK inhibitor for vitiligo suddenly 6 million people in this country would be eligible for treatment. If only 5% of those get treated it will represent an almost $2 billion new income stream for Avita. And that's not pie in the sky, this will happen for Recell next year and a similar time frame for the JAK inhibitor.
Just read this from the Hot Copper forums:
Honestly Renovacare was never going to be a competitor, their CEO is a bona-fide crook. It's finally showing up in multiple shareholder lawsuits. Lawyers might make some money.
My initial post was to identify a company Renovacare (RCAR) that has a treatment procedure similar to RECELL. They have initiated action (see hyperlink) to diminish their position as a competitor to RECELL market advancement.
VALENCIA, Calif. and MELBOURNE, Australia, May 12, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, today reported financial results for its first quarter ended March 31, 2022.
Financial Highlights and Recent Updates:
Reported commercial revenue, which excludes BARDA revenue, of $7.4 million a 61% increase compared to $4.6 million in the corresponding period in the prior year
Reported total revenue, which includes BARDA revenue, of $7.5 million compared to $8.8 million in the corresponding period in the prior year, which included $4.1 million in BARDA revenue
In February 2022, FDA approved our premarket approval application (PMA) supplement for RECELL® Autologous Cell Harvesting Device, an enhanced RECELL system aimed at providing clinicians a more efficient user experience and simplified workflow
In February 2022, Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) approved our application for commercialization of the RECELL system in burns
As of March 31, 2022, the Company had $95.0 million in cash, cash equivalents, and marketable securities, with no debt
“Our commercial team performed well this quarter driving further adoption and penetration within burn centers, and our clinical team continued to move the soft tissue reconstruction and vitiligo trials forward,” said Dr. Mike Perry, AVITA Medical Chief Executive Officer. “We are well positioned to drive revenue growth ahead and we look forward to topline data readouts from our soft tissue reconstruction and vitiligo clinical trials in the second half of this year.”
First Quarter of Year 2022 Financial Results
Our commercial revenue, which excludes BARDA revenue, was $7.4 million in the current year, an increase of $2.8 million or 61%, compared to $4.6 million the corresponding period in the prior year. Total revenue, which includes BARDA revenue, was $8.8 million in the corresponding period in the prior year which included $4.1 million in BARDA related revenue that resulted from our delivery of units to managed inventory for BARDA for emergency response preparedness. The increase in commercial revenue was largely driven by broader utilization among our customer base as well as deeper penetration within individual customer accounts.
Gross profit margin was 76% and is flat compared to the corresponding period in the prior year.
Total operating expenses increased by 21% to $16.0 million compared to $13.2 million in the corresponding period in the prior year. The increase in operating expenses is primarily attributable to higher share-based compensation, salary, and benefits. Higher share-based compensation expenses are associated with acceleration of expense for certain performance milestones being met in the current quarter. Higher salary and benefits are driven by the expansion of our workforce to support the overall operations, an increase in field resources to expand our market coverage and hiring of an executive at the end of March 2021.
Net loss increased by 58% or $3.5 million to $9.5 million, or $0.38 per share, compared to a net loss of $6.0 million, or $0.26 per share, in the corresponding period of the prior year.
Adjusted EBITDA* loss increased by 42%, or $1.9 million to $6.4 million, over the $4.5 million recognized in the corresponding period in the prior year. A table reconciling non-GAAP measures is included in this press release for reference.
Calendar Year 2022 Revenue Guidance
Commercial revenues in calendar year 2022 are projected to be approximately $30 million, excluding BARDA revenues, which represents a 20% increase year-over year. We project BARDA revenues of approximately $0.3 million in calendar year 2022, as compared to $7.9 million in calendar year 2021, since we completed delivery of RECELL units into the national stockpile in 2021.
*Adjusted EBITDA is a non-GAAP financial measure. See the appendix to this release for a discussion of Non-GAAP financial measures, including a reconciliation to the most closely correlated GAAP measure.
Webcast and Conference Call Information
The Company will host a conference call to discuss the first quarter financial results after market close on Thursday May 12, 2022, at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time (being 6.30 a.m. Australian Eastern Standard Time on Friday May 13, 2022). The conference call can be accessed live over the phone at (833) 614-1538 for U.S. callers or at (706) 634-6548 international callers, using conference ID:2592487. The live webinar can be accessed at https://ir.avitamedical.com.
Authorized for release by the Chief Financial Officer of AVITA Medical, Inc.
ABOUT AVITA Medical, Inc.
AVITA Medical, Inc. is a regenerative medicine company with a technology platform positioned to address unmet medical needs in burns, chronic wounds, and aesthetics indications. AVITA Medical Inc. patented, and proprietary collection and application technology provides innovative treatment solutions derived from the regenerative properties of a patient’s own skin. The medical devices work by preparing a RES® REGENERATIVE EPIDERMAL SUSPENSION, an autologous suspension comprised of the patient’s skin cells necessary to regenerate natural healthy epidermis. This autologous suspension is then sprayed onto the areas of the patient requiring treatment.
AVITA Medicals’ first U.S. product, the RECELL System, was approved by the U.S. Food and Drug Administration (FDA) in September 2018. The RECELL System is approved for acute partial-thickness thermal burn wounds in patients 18 years of age and older or application in combination with meshed autografting for acute full-thickness thermal burn wounds in pediatric and adult patients. The RECELL System is used to prepare Spray-On Skin™ Cells using a small amount of a patient’s own skin, providing a new way to treat severe burns, while significantly reducing the amount of donor skin required. The RECELL System is designed to be used at the point of care alone or in combination with autografts depending on the depth of the burn injury. Compelling data from randomized, controlled clinical trials conducted at major U.S. burn centers and real-world use in more than 8,000 patients globally, reinforce that the RECELL System is a significant advancement over the current standard of care for burn patients and offers benefits in clinical outcomes and cost savings. Healthcare professionals should read the INSTRUCTIONS FOR USE - RECELL Autologous Cell Harvesting Device (https://recellsystem.com/) for a full description of indications for use and important safety information including contraindications, warnings, and precautions.
In February 2022, the FDA reviewed and approved the PMA supplement for RECELL Autologous Cell Harvesting Device, an enhanced RECELL System aimed at providing clinicians a more efficient user experience and simplified workflow. The RECELL System is a device that enables healthcare professionals to produce a suspension of Spray-On Skin™ Cells using a small sample of the patient’s own skin for the treatment of acute thermal burns
In international markets, our products are marketed under the RECELL System brand to promote skin healing in a wide range of applications including burns, chronic wounds, and aesthetics. The RECELL System is TGA-registered in Australia and received CE-mark approval in Europe.
To learn more, visit www.avitamedical.com.
* Use of Non-GAAP Measure
AVITA Medical’s reported earnings are prepared in accordance with generally accepted accounting principles in the United States, or GAAP, and represent earnings as reported to the Securities and Exchange Commission. AVITA Medical has provided in this release certain financial information that has not been prepared in accordance with GAAP. AVITA Medical’s management believes that the non-GAAP adjusted EBITDA described in the release, which includes adjustments for specific items that are generally not indicative of our core operations, provides additional information that is useful to investors in understanding AVITA Medical’s underlying performance, business and performance trends, and helps facilitate period-to-period comparisons and comparisons of its financial measures with other companies in AVITA Medical’s industry. However, the non-GAAP financial measures that AVITA Medical uses may differ from measures that other companies may use. Non-GAAP financial measures are not required to be uniformly applied, are not audited and should not be considered in isolation or as substitutes for results prepared in accordance with GAAP.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “intend,” “could,” “may,” “will,” “believe,” “estimate,” “look forward,” “forecast,” “goal,” “target,” “project,” “continue,” “outlook,” “guidance,” “future,” other words of similar meaning and the use of future dates. Forward-looking statements in this press release include, but are not limited to, statements concerning, among other things, our ongoing clinical trials and product development activities, regulatory approval of our products, the potential for future growth in our business, and our ability to achieve our key strategic, operational, and financial goals. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Each forward- looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the timing of regulatory approvals of our products; physician acceptance, endorsement, and use of our products; failure to achieve the anticipated benefits from approval of our products; the effect of regulatory actions; product liability claims; risks associated with international operations and expansion; and other business effects, including the effects of industry, economic or political conditions including, but not limited to the ongoing COVID-19 pandemic which are outside of the company’s control. Investors should not place considerable reliance on the forward-looking statements contained in this press release. Investors are encouraged to read our publicly available filings for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this release, and we undertake no obligation to update or revise any of these statements
Can you repeat that in English, please?
Sounds worth understanding, but between your post and the broken link, I’m confluffliflixicated.
Cheers
As melody suggested, the 30 minute mark and after IS A MUST LISTEN.
SPIKE!
New corporate deck out on ASX Australia, should be out here before open. Shows 61% Y/Y growth from Q1 2021 to Q1 2022 and 8% growth over last quarter of 7.446 million from 6.9 million.
20 million total cash burn for the year which is actually exceptional for a year that saw 3 FDA clinical trials and the rollout of a new product during a pandemic.
Might be a good time to put a toe in.
It's much worse than that. 2020 we were at $55, now all the way back down to 5, same price as before the RS. F'n RS's Don't WORK. I know RCEL has great tech but are they ever going to make a go of it?
RECELL® System to be Highlighted at Upcoming Music City SCALE Multidisciplinary Dermatology Meeting
PDF Version
VALENCIA, Calif. and MELBOURNE, Australia, May 09, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (Company), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that a discussion on the RECELL System will be held during the Symposium for Cosmetic Advances & Laser Education (SCALE) multidisciplinary dermatology meeting taking place May 11-15 in Nashville, TN. SCALE is the premier multidisciplinary meeting for aesthetic medicine, plastic surgery and medical dermatology.
The presentation will feature Dr. Jeffrey Carter, FACS, Associate Professor of Surgery and Medical Director, UMCNO Burn Center at LSU Health in New Orleans, who will discuss the use of the RECELL System for treatment of burn injuries. Additionally, Dr. Seemal Desai, FAAD, Diplomate of the American Board of Dermatology, and a Board-Certified Dermatologist, will review the clinical trial protocol aimed at establishing safety and effectiveness for repigmentation of stable vitiligo lesions utilizing the RECELL System. The discussion, “RECELL: A Novel Treatment Strategy for Regenerative & Restorative Skin Conditions” will take place Thursday, May 12 from 2:30-2:40 pm CDT.
“It is important for us to share clinical evidence and peer insights related to the RECELL System with leaders of the dermatology community to help physicians make educated treatment decisions for their patients,” said Dr. Mike Perry, Chief Executive Officer of AVITA Medical. “As we pursue the vitiligo indication, our vision is to offer the community an innovative solution to better serve the millions of people who suffer with this disease.”
Vitiligo is a disease that attacks pigment-producing cells, called melanocytes, resulting in their destruction or malfunction. The result is a loss of pigmentation in patches of skin. Vitiligo affects up to 2% of the population worldwide,i including an estimated 3-6.5 million Americans.ii Vitiligo has a comparable market size and psychosocial impact to other major dermatology diseases including psoriasis (thick, scaly skin) and atopic dermatitis (red, cracked skin).iiiivv Like these diseases, those living with vitiligo may suffer from poor body image along with low self-esteem, leading to an impaired quality of life.vi
AVITA Medical is currently completing a pivotal trial for the use of the RECELL System for treatment of stable vitiligo. Currently, the RECELL System is indicated in the U.S. for treatment of acute thermal burns. Our vitiligo clinical trial aims to demonstrate safe and effective repigmentation when using the RECELL System in combination with phototherapy. Topline data from the trial will be shared later this year.
ABOUT AVITA MEDICAL, INC.
AVITA Medical is a regenerative medicine company with a technology platform positioned to address unmet medical needs in burns, chronic wounds, and aesthetics indications. AVITA Medical’s patented and proprietary collection and application technology provides innovative treatment solutions derived from the regenerative properties of a patient’s own skin. The medical devices work by preparing a RES® REGENERATIVE EPIDERMAL SUSPENSION, an autologous suspension comprised of the patient’s skin cells necessary to regenerate natural healthy epidermis. This autologous suspension is then sprayed onto the areas of the patient requiring treatment.
AVITA Medical’s first U.S. product, the RECELL® System, was approved by the U.S. Food and Drug Administration (FDA) in September 2018. The RECELL System is indicated for use in the treatment of acute thermal burns. The RECELL System is used to prepare Spray-On Skin™ Cells using a small amount of a patient’s own skin, providing a new way to treat severe burns, while significantly reducing the amount of donor skin required. The RECELL System is designed to be used at the point of care alone or in combination with autografts depending on the depth of the burn injury. Compelling data from randomized, controlled clinical trials conducted at major U.S. burn centers and real-world use in more than 10,000 patients globally reinforce that the RECELL System is a significant advancement over the current standard of care for burn patients and offers benefits in clinical outcomes and cost savings. Healthcare professionals should read the INSTRUCTIONS FOR USE - RECELL® Autologous Cell Harvesting Device (https://recellsystem.com/) for a full description of indications for use and important safety information including contraindications, warnings, and precautions.
In international markets, our products are marketed under the RECELL System brand to promote skin healing in a wide range of applications including burns, chronic wounds, and aesthetics. The RECELL System is TGA-registered in Australia and received CE-mark approval in Europe. To learn more, visit www.avitamedical.com.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “intend,” “could,” “may,” “will,” “believe,” “estimate,” “look forward,” “forecast,” “goal,” “target,” “project,” “continue,” “outlook,” “guidance,” “future,” other words of similar meaning and the use of future dates. Forward-looking statements in this press release include, but are not limited to, statements concerning, among other things, our ongoing clinical trials and product development activities, regulatory approval of our products, the potential for future growth in our business, and our ability to achieve our key strategic, operational and financial goal. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the timing of regulatory approvals of our products; physician acceptance, endorsement, and use of our products; failure to achieve the anticipated benefits from approval of our products; the effect of regulatory actions; product liability claims; risks associated with international operations and expansion; and other business effects, including the effects of industry, economic or political conditions outside of the company’s control. Investors should not place considerable reliance on the forward-looking statements contained in this press release. Investors are encouraged to read our publicly available filings for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this release, and we undertake no obligation to update or revise any of these statements.
This press release was authorized by the review committee of AVITA Medical, Inc.
It appears that a potential competitor of RCEL has decided to mark time on specific
Strategic R&D Agreement with StemCell Systems and the closure of the RenovaCare R&D Innovation Center in Berlin, Germany. It indicates the RCEL moat has grown wider.
https://app.getresponse.com/click.html?x=a62b&lc=hBM259&mc=C2&s=eGg6zv&u=Hjbx&z=EhZ0BYO&
Hi guys
I would like to take this opportunity to thank the BOD for absolutely fucking up this This company with the absolute greed For their own personal gain without a single thought for any shareholder long-term or short-term that really believes in the product that could do good for many thousands of people I hope with all my heart they read this and take some note you greedy b satrds
Hi guys
I would like to take this opportunity to thank the BOD for absolutely fucking up this This company with the absolute greed For their own personal gain without a single thought for any shareholder long-term or short-term that really believes in the product that could do good for many thousands of people I hope with all my heart they read this and take some note you greedy b satrds
I own a bit of another medical device company TMDX. Similar to Avita in its dominance of it's field (though not nearly the TAM of RCEL). She too languished until the executives guided to 68-80% yoy growth. IMO until Avita's numbers reflect the promise of her technology she likely will continue to drift. When she does put up the numbers in line with her potential, she will shoot up. Til then she is a hostage to news cycles on progress with the FDA and or Japan.
I think it has more to do with financial markets repeatedly bleeding red, double-digit inflation, high gas prices, & etc. The entire biotech market has been getting hammered...not just Avit.
Hi guys
Once again this share is falling through the floor apart from a member of the board resigning any other good reasons anyone can think of
Regards steve
Just so you know, I am still invested in RCEL. This is ThaYoda from the Yahoo boards. I haven't been posting because some people in the forums must have reported me for whatever, so I am unable to post at all on Yahoo. I did not sell, and I am holding for at least 3-5 years.
Followers
|
102
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
7485
|
Created
|
06/20/12
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |